#USA #Burlington #financial results #Life Sciences #Azenta Inc

Azenta's Fiscal Year 2026 Financial Results

On November 10, 2026, Azenta, Inc. (Nasdaq: AZTA), a leading name in life sciences solutions, disclosed its financial results for the fourth quarter and the entirety of fiscal year 2026, concluding on September 30, 2026. This release highlights a promising growth trajectory and strategic corporate actions that aim to enhance the company’s market presence in the life sciences industry.

Financial Highlights

In the fourth quarter of fiscal 2026, Azenta reported revenues of $167 million, reflecting a 5% growth year over year. When excluding minor foreign exchange impacts, the organic revenue growth stood at 2%. This uptrend is largely attributed to robust performance in Sample Management Solutions and the acquisition of UK Biocentre Limited, although it faced some challenges in the Multiomics segment due to a decline in Sanger Sequencing revenue.

For the entire fiscal year, total revenues reached $622 million, marking a 5% increase compared to fiscal 2025. The breakdown of revenue by segment showcases the growth in Sample Management Solutions, which garnered revenues of $344 million, up from $325 million in the previous year, driven primarily by gains across Sample Repository Services and related instruments.

Operational Performance

Despite facing challenges, including increased operational expenses and a goodwill impairment of $149 million, Azenta is adjusting its focus on operational efficiency. The adjusted gross margin stood at 47.2% in Q4, and the adjusted EBITDA margin was 11.6%, even though these figures reflect slight decreases from the previous fiscal quarter.

Operating income for Q4 2026 was reported at $2.5 million, with a gross margin of 46.0%, both of which represent substantial progress despite some impacts from lower sales volumes in certain portfolio areas.

Strategic Initiatives

Azenta has initiated several strategic moves, including the introduction of agreements with Elegen Corp. at the end of October 2026 to bolster its gene synthesis capabilities. The agreements involve exclusive licenses to innovative technologies, which are expected to enhance Azenta's Multiomics business segment. Furthermore, Azenta acquired SynPlexity Inc., a synthetic biology company, with an initial cash payment of $15 million, aimed at advancing its gene synthesis offerings.

Stock Performance & Forecast

Management is optimistic about fiscal year 2027, expecting total reported revenues to range between $648 million and $660 million, with an anticipated organic growth rate of 3% to 5%. Azenta's strategic outlook emphasizes improving execution and accelerating overall performance as they capitalize on the acquisitions and expansions made to their portfolio.

Furthermore, Azenta's Board of Directors has a share repurchase program, which aims to repurchase up to $250 million of common stock by 2028. In the past fiscal year, they successfully repurchased 4.4 million shares for $118.2 million, highlighting their commitment to returning value to shareholders while navigating through transitions in the market.

Conclusion

As Azenta moves forward, it is poised to expand its footprint in the life sciences sector through innovative technology agreements and acquisitions. The strategic focus on enhancing profitability and cash generation, along with their proactive approach in managing operational challenges, sets a robust foundation for the forthcoming fiscal year. Investors and stakeholders can anticipate updates during the upcoming fiscal conference call, where management will further elaborate on these strategies and financial forecasts.